Biogen Inc. (BIIB) financial statements and ratios from SEC XBRL: revenue $9.89B (TTM), net margin 13.1%, revenue growth 1.9% YoY, P/E 23.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $9.89B |
| Net Margin | 13.1% |
| Revenue Growth (YoY) | 1.9% |
| EPS Growth (YoY) | 31.5% |
| FCF Growth (YoY) | 167.5% |
| P/E Ratio | 23.1 |
| EV / EBITDA | 14.3 |
| Price / Book | 1.70 |
| Price / Sales | 3.19 |
| FCF Yield | 7.6% |
| DCF Value (model) | $71.33 |
| DCF Upside vs Price | -66.8% |
| Altman Z-Score | 3.41 (safe) |
| Piotroski F-Score | 5/9 |
| Sector P/E (Healthcare) | 21.6 |
BIIB overview · BIIB earnings · BIIB KPIs · BIIB investor relations · BIIB ownership · BIIB peers · BIIB filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.